Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoRecormon, CellCept and Prednisone in Low/Intermediate Risk MDS
NCT00551291Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2007
- Primary completion
- Jun 2009
- Modality
- Erythropoietins, Colony Stimulating Factors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mycophenolate mofetil, epoetin beta in myelodysplastic syndrome (MDS), sponsored by Roche. Started Aug 2007; status: completed.
02
Drugs
mycophenolate mofetilepoetin beta
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00551291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551291.